Human papillomavirus 9-valent vaccine, recombinant + human papillomavirus vaccine, recombinant
ApprovedRecruiting 1 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Papillomavirus Vaccines
Conditions
Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology, Cervical Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Oral Cavity Infection
Trial Timeline
Nov 30, 2022 → Jun 1, 2026
NCT ID
NCT05266898About Human papillomavirus 9-valent vaccine, recombinant + human papillomavirus vaccine, recombinant
Human papillomavirus 9-valent vaccine, recombinant + human papillomavirus vaccine, recombinant is a approved stage product being developed by Merck for Papillomavirus Vaccines. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05266898. Target conditions include Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection.
What happened to similar drugs?
2 of 20 similar drugs in Papillomavirus Vaccines were approved
Approved (2) Terminated (0) Active (18)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05266898 | Approved | Recruiting |
Competing Products
20 competing products in Papillomavirus Vaccines